false --12-31 0002094256 8-K12B Beacon Topco, Inc. 0002094256 2026-11-20 2026-11-20 0002094256 dei:FormerAddressMember 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 20, 2026

 

CLYWEDOG THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40367   41-2339925
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

8 The Green, Suite 8666

Dover, Delaware 19901

(Address of principal executive offices, including zip code)

 

(302) 385-8535

(Registrant’s telephone number, including area code)

 

Beacon Topco, Inc.

20400 Century Boulevard, Suite 210

Germantown, MD 20874

United States of America

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
 
Common Stock, $0.0001 par value per share* CLYD The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

* This report is filed by the registrant as the successor issuer to Barinthus Biotherapeutics plc. The American Depositary Shares of Barinthus Biotherapeutics plc, each representing one ordinary share, were previously registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and listed on The Nasdaq Stock Market under the symbol “BRNS.” The registrant’s common stock is deemed to be registered under Section 12(b) of the Exchange Act by virtue of Rule 12g-3(a) promulgated thereunder.

 

 

 

 

 

INTRODUCTORY NOTE

 

As previously disclosed, on September 9, 2026 (the “Scheme Effective Time”), pursuant to a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the “Scheme of Arrangement”) and as contemplated by the previously disclosed Agreement and Plan of Merger, dated September 29, 2025 (the “Original Merger Agreement”), as amended by that certain Amendment to the Agreement and Plan of Merger dated February 22, 2026 (the “Amendment No. 1 to Merger Agreement”), by and among Barinthus Biotherapeutics plc (“Barinthus Bio”), Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc., the “Company”), Cdog Merger Sub, Inc. (“Merger Sub”) and Clywedog Therapeutics, Inc. (“Clywedog”), the entire issued and to be issued share capital of Barinthus Bio was acquired by the Company and Barinthus Bio became a wholly-owned subsidiary of the Company. On September 22, 2026, the parties to the Original Merger Agreement entered into that certain Amendment No. 2 to the Agreement and Plan of Merger (the “Amendment No. 2 to Merger Agreement”) and on October 31, 2026, the parties to the Original Merger Agreement entered into that certain Amendment No. 3 to the Agreement and Plan of Merger (the “Amendment No. 3 to Merger Agreement”, and, together with the Original Merger Agreement, the Amendment No. 1 to Merger Agreement and the Amendment No. 2 to Merger Agreement, the “Merger Agreement”).

 

On November 20, 2026 (the “Merger Effective Time”), the Company, Merger Sub and Clywedog consummated the merger of Merger Sub with and into Clywedog, with Clywedog surviving as a direct wholly owned subsidiary of the Company pursuant to the terms of the Merger Agreement (the “Merger” and together with the Scheme Transaction (as defined below), the “Combinations”). Pursuant to the Combinations, the Company became the parent company for the combined businesses of Barinthus Bio and Clywedog.

 

As a result of the Combinations, the Company became the successor issuer to Barinthus Bio pursuant to Rule 12g-3(a) under the Exchange Act. This Current Report on Form 8-K (this “Form 8-K”) is being filed for the purpose of establishing the Company as the successor issuer pursuant to Rule 12g-3(a) and to disclose certain related matters. Pursuant to Rule 12g-3(a), shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), are deemed registered under Section 12(b) of the Exchange Act.

 

Item 2.01Completion of Acquisition or Disposition of Assets.

 

The information contained in the Introductory Note of this Form 8-K is incorporated by reference into this Item 2.01.

 

Pursuant to the Merger Agreement, the Combinations were implemented as follows: (i) on September 9, 2026, the Company acquired the entire issued and to be issued share capital of Barinthus Bio pursuant to (a) the Scheme of Arrangement, (b) a share purchase agreement pursuant to which the deferred A shares in the capital of Barinthus Bio were acquired by the Company upon effectiveness of the Scheme of Arrangement, and (c) the Merger Agreement (such transaction, together with the Scheme of Arrangement, the “Scheme Transaction”), resulting in Barinthus Bio becoming a direct wholly owned subsidiary of the Company, and (ii) on November 20, 2026, Merger Sub merged with and into Clywedog, with Clywedog continuing as the surviving corporation and a direct wholly owned subsidiary of the Company in accordance with the Delaware General Corporation Law.

 

Pursuant to the Scheme Transaction, upon the terms and subject to the conditions set forth in the Merger Agreement, the Company acquired each outstanding ordinary share of Barinthus Bio, with a par value of £0.000025 per share (the “Barinthus Ordinary Shares,” and each such acquired Barinthus Ordinary Share, a “Scheme Share”), which, for the avoidance of doubt, included Barinthus Ordinary Shares held by The Bank of New York Mellon (the “Depositary”) (and represented by American Depositary Shares (the “Barinthus ADSs”), each representing one (1) Barinthus Ordinary Share, issued pursuant to the deposit agreement, dated as of April 29, 2021, among Barinthus Bio, the Depositary, and all holders from time to time of the Barinthus ADSs, as may be amended from time to time), from the holders of Scheme Shares whose names appeared in the register of members of Barinthus Bio on September 9, 2026, in accordance with the provisions of the Scheme of Arrangement, and each Scheme Share was converted into the right to receive (i) 0.111111 shares of Common Stock, rounded down to the nearest whole share, plus (ii) cash in lieu of any fraction of a share, each subject to and strictly in accordance with the terms of the Scheme of Arrangement (collectively, the “Scheme Consideration”).

 

At the Merger Effective Time, subject to adjustment in accordance with the terms of the Merger Agreement, each share of common stock, $0.0001 par value per share, of Clywedog (the “Clywedog Common Stock”) and each share of Series Seed Preferred Stock, $0.0001 par value per share, of Clywedog (the “Clywedog Preferred Stock,” and together with the Clywedog Common Stock, the “Clywedog Shares”), other than Clywedog Shares held as treasury stock or owned by the Company or Merger Sub immediately prior to the Merger Effective Time, was converted solely into the right to receive (i) 0.741416 shares of Common Stock, rounded down to the nearest whole share, plus (ii) cash in lieu of any fraction of a share (collectively, the “Merger Consideration”). For accounting purposes, Clywedog is considered to be the accounting acquiror, and its historical financial statements will continue to be those of the combined company following the Merger.

 

As a result of the Combinations, former Barinthus Bio shareholders own approximately 34% and former Clywedog stockholders own approximately 66% of the Company on a fully diluted basis.

 

The issuance of Common Stock in connection with the Combinations was registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s registration statement on Form S-4 (File No. 333-291359) initially filed with the U.S. Securities and Exchange Commission (“SEC”) on November 7, 2025 (as amended, the “Registration Statement”), and declared effective on April 22, 2026. The proxy statement/prospectus, dated April 22, 2026, that forms a part of the Registration Statement contains additional information about the Combinations and the other transactions contemplated by the Merger Agreement, including a description of the treatment of equity awards and information concerning the interests of directors, executive officers and affiliates of the Company, Barinthus Bio and Clywedog in the Combinations.

 

 

 

The Common Stock was approved for listing on The Nasdaq Capital Market (“Nasdaq”). Prior to the Combinations, the Barinthus ADSs, representing Barinthus Ordinary Shares, were registered pursuant to Section 12(b) of the Exchange Act and listed on Nasdaq. In connection with the effectiveness of the Scheme of Arrangement, Barinthus Bio (i) requested that Nasdaq suspend trading of the Barinthus ADSs effective before the opening of trading on September 9, 2026, and (ii) filed with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to delist and deregister the Barinthus ADSs under Section 12(b) of the Exchange Act. Following the effectiveness of the Scheme of Arrangement, there are no Barinthus ADSs issued or outstanding, and following the suspension of trading of the Barinthus ADSs on Nasdaq on September 9, 2026 prior to the market opening, there is no public trading market for the Barinthus ADSs. On September 21, 2026, Barinthus Bio filed with the SEC a certification on Form 15 under the Exchange Act, requesting the suspension of Barinthus Bio’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

 

On November 20, 2026, the Company changed its name to “Clywedog Therapeutics Holdings, Inc.” and on November 23, 2026 its Common Stock is expected to commence trading on Nasdaq under the symbol “CLYD.”

 

The foregoing description of the Merger Agreement and the Combinations does not purport to be complete and is qualified in its entirety by reference to the full text of the Original Merger Agreement, Amendment No. 1 to Merger Agreement, Amendment No. 2 to Merger Agreement, and Amendment No. 3 to Merger Agreement filed as Exhibits 2.1, 2.2, 2.3 and 2.4 hereto, respectively, and incorporated into this Item 2.01 by reference. The Merger Agreement has been included to provide investors with information regarding its terms. It is not intended to provide any other factual information about the Company, Barinthus Bio, Clywedog or their respective subsidiaries or affiliates or to modify or supplement any factual disclosures about the Company or Barinthus Bio in their public reports filed with the SEC. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of the Merger Agreement and as of specific dates, were solely for the benefit of the respective parties to the Merger Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the respective parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or of any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s, Barinthus Bio’s or Clywedog’s respective public disclosures.

 

As of the Scheme Effective Time, the Company believed that the Scheme Transaction would be accounted for as a common control transaction and thus the filing of financial statements was not required. However, upon subsequent analysis the Company determined that the Merger was significant and probable as of the Scheme Effective Time. Accordingly, the Company files the following historical financial statements and pro forma financial information required by Item 9.01 of Form 8-K in connection with the Scheme Transaction: (i) the unaudited condensed consolidated financial statements of Clywedog as of June 30, 2026 and December 31, 2025 and for the three and six months ended June 30, 2026 and 2025, which are filed as Exhibit 99.1 hereto and incorporated herein by reference and (ii) the unaudited pro forma condensed combined financial statements of the Company as of and for the six months ended June 30, 2026 and for the year ended December 31, 2025, which are filed as Exhibit 99.2 hereto and incorporated herein by reference.

 

Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

The information set forth in Item 2.01 of this Form 8-K is incorporated by reference into this Item 3.01.

 

Item 3.03Material Modification to Rights of Security Holders.

 

The information set forth in Items 2.01 and 5.03 of this Form 8-K is incorporated by reference into this Item 3.03.

 

As previously disclosed, upon consummation of the Scheme Transaction, each Scheme Share was exchanged for the Scheme Consideration. Upon consummation of the Merger, each share of Clywedog Common Stock and Clywedog Preferred Stock was converted into the Merger Consideration. As a result of the Combinations, former Barinthus Bio shareholders own approximately 34% and former Clywedog stockholders own approximately 66% of the Company on a fully diluted basis. Each share of Common Stock is issued pursuant to, and carries with it the rights and obligations set forth in, the Amended and Restated Certificate of Incorporation of the Company, effective September 9, 2026 (the “A&R Certificate of Incorporation”), as amended by the Certificate of Amendment (defined below), which are filed as Exhibits 3.1 and 3.2 hereto, respectively, and incorporated into this Item 3.03 by reference.

 

Also in connection with the Combinations, upon the effectiveness of the Scheme (i) each option to acquire Barinthus Ordinary Shares that was outstanding and unvested immediately prior to the effectiveness of the Scheme automatically and without any required action on the part of the holder thereof accelerated in full and fully vested, and the shares underlying such vested Barinthus Bio options converted into an option to purchase shares of Company Common Stock on the same terms and conditions as were applicable to such Barinthus Bio option immediately prior to the effectiveness of the Scheme, and (ii) each restricted share unit outstanding previously granted by Barinthus Bio, whether or not vested, was converted into a restricted stock unit relating to Company Common Stock of the same type and on the same terms and conditions as were applicable to the corresponding restricted share unit granted by Barinthus Bio. 

 

Item 5.01Changes in Control of Registrant.

 

The information set forth in Item 2.01 of this Form 8-K is incorporated by reference into this Item 5.01.

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of Director and Appointment of Directors of the Company

 

Immediately prior to the appointment of the below-mentioned members of the Company’s board of directors, Nick Fullenkamp resigned as a director of the Company. Mr. Fullenkamp’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

Pursuant to the Merger Agreement, Clywedog was entitled to designate at least 2/3 of the directors of the Company prior to the Merger Effective Time, and Barinthus Bio was entitled to designate at least 1/3 of the directors of the Company prior to the Merger Effective Time. At the Merger Effective Time, the following individuals were appointed as members of the Company’s board of directors: Iain Dukes, Trafford Clarke, John M. McGill and Robin Wright, each of whom, other than Mr. Dukes, qualifies as an “independent director” under the applicable rules of Nasdaq.

 

 

 

There are no arrangements or understandings between any director and any other person pursuant to which the director was selected as a director.

 

As described in Item 3.03 above, which information is incorporated by reference into this Item 5.02, in connection with the Combinations the options to acquire Barinthus Ordinary Shares held by William Enright and Robin Wright were converted into options to purchase shares of Company Common Stock on the same terms and conditions as were applicable to such Barinthus Bio options immediately prior the effectiveness of the Scheme.

 

At the Merger Effective Time and prior to the listing of Common Stock on Nasdaq, the board of directors established an Audit Committee (the “Audit Committee”), a Compensation Committee (the “Compensation Committee”) and a Nominating and Governance Committee (the “Nominating and Governance Committee”), and appointed directors to such committees as follows:

 

Audit Committee: Trafford Clarke (Chair)
John M. McGill
Robin Wright
   
Compensation Committee: John M. McGill (Chair)
  Trafford Clarke
  Robin Wright  
   
Nominating and Governance Committee: Robin Wright (Chair)
Trafford Clarke
  John M. McGill

 

There are no family relationships among any of the directors or executive officers of the Company, and none of the newly appointed directors has a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Appointment of Officers of the Company

 

At the Merger Effective Time, each of the following individuals (the “Executive Officers”) was appointed as an “officer” (within the meaning of Section 16 of the Exchange Act) and an “executive officer” of the Company for purposes of Rule 3b-7 under the Exchange Act:

 

Name Title
Iain Dukes Executive Chairman
Leon Hooftman Chief Medical Officer
Douglas Swirsky Chief Financial Officer

 

As described in Item 3.03 above, which information is incorporated by reference into this Item 5.02, in connection with the Combinations the restricted share unit outstanding previously granted by Barinthus Bio to Mr. Hooftman was converted into a restricted stock unit relating to Company Common Stock of the same type and on the same terms and conditions as were applicable to the corresponding restricted share unit granted by Barinthus Bio.

 

Douglas Swirsky, age 56, has over 25 years of experience in a wide range of industries. Mr. Swirsky has served as Chief Financial Officer of Barinthus Bio since May 2026 and as the founder and principal of Grand Strand BioAdvisors LLC since April 2026. Mr. Swirsky served as Chief Financial Officer of MaxCyte, Inc. from March 2023 to March 2026. He then served as a Senior Advisor to MaxCyte until May 2026 and has provided consulting services to MaxCyte since June 2026. Prior to that, Mr. Swirsky served as Chief Financial Officer and Treasurer of AavantiBio, Inc. from February 2021 until its acquisition by Solid Biosciences, Inc. in December 2022. Before that, Mr. Swirsky served as President, Chief Executive Officer and a director of Rexahn Pharmaceuticals, Inc. from November 2018 until November 2020. Mr. Swirsky has served as a director of Cellectar Biosciences, Inc. since 2017 and currently serves as chairman of its board of directors. Previously, Mr. Swirsky also served on the board of directors of NeuroBo Pharmaceuticals, Inc. from 2020 to 2022, including as its chairman from 2021 to 2022. Mr. Swirsky is a certified public accountant in the state of Maryland and a CFA charterholder. He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University.

 

At the Merger Effective Time, Mr. Swirsky will serve as the Company’s Chief Financial Officer on an “at-will” basis, the terms and conditions of which are subject to negotiation between the Company and Mr. Swirsky.

 

No family relationships exist between Mr. Swirsky and any of the Company’s directors or executive officers. There are no arrangements or understandings between Mr. Swirsky and any other person pursuant to which Mr. Swirsky was selected as the Chief Financial Officer, nor are there any transactions to which the Company is or was a participant in which Mr. Swirsky has a material interest subject to disclosure pursuant to Item 404(a) of Regulation S-K.

 

 

 

Amendment to Mr. Enright’s Employment Agreement

 

At the Merger Effective Time, Mr. Enright will serve as the Company’s Chief Executive Officer pursuant to that certain Amendment to Employment Agreement, dated as of November 20, 2026, by and among Barinthus Bio, Barinthus Biotherapeutics North America, Inc. (“Barinthus Bio North America”), the Company and William Enright (the “Enright Employment Agreement Amendment”). Pursuant to the Enright Employment Agreement Amendment, the Company joined that certain Employment Agreement, effective as of the closing of Barinthus Bio’s initial public offering in May 2021, by and among Mr. Enright, Barinthus Bio and Barinthus Bio North America (the “Original Enright Employment Agreement” and together with the Enright Employment Agreement Amendment, the “Enright Employment Agreement”) and agreed to be bound by the terms and conditions of the Original Enright Employment Agreement. Pursuant to the Enright Employment Agreement, Mr. Enright is entitled to an annual base salary, subject to periodic increase (but not decrease), target annual bonus opportunity and employee benefits. Under the Enright Employment Agreement, in the event that Mr. Enright’s employment is terminated by the Company without “cause” or Mr. Enright resigns for “good reason” (as such terms are defined in the Enright Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in the Company’s favor), he will be entitled to receive (i) an amount equal to 12 months of his base salary, payable over the 12 month period following his termination, (ii) if his termination occurs following completion of a calendar year but prior to payment of an annual bonus, payment of such annual bonus, and (iii) if Mr. Enright is participating in the Company’s group health plans immediately prior to his termination and elects COBRA health continuation, continuation of such group health coverage at the same rate as if he were an active employee, until the earliest of (A) the 12 month anniversary of his termination; (B) his eligibility for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of his continuation rights under COBRA. The Enright Employment Agreement also provides that, in lieu of the payments and benefits described above, in the event that Mr. Enright’s employment is terminated by the Company without cause or Mr. Enright resigns for good reason, in either case within 12 months following a “change in control” (as defined in the Enright Employment Agreement), subject to the execution and effectiveness of a general release of claims in the Company’s favor, he will be entitled to receive (i) a lump sum cash payment equal to 1.5 times the sum of his then-current base salary (or his base salary in effect immediately prior to the change in control, if higher) plus his annual target bonus for the then-current year (or the annual target bonus in effect immediately prior to the change in control, if higher), and (ii) if Mr. Enright is participating in the Company’s group health plans immediately prior to his termination and elects COBRA health continuation, continuation of such group health coverage at the same rate as if he were an active employee, until the earliest of (A) the 18 month anniversary of his termination; (B) his eligibility for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of his continuation rights under COBRA. The Enright Employment Agreement further provides that in the event Mr. Enright’s employment is terminated by the Company without cause or Mr. Enright resigns for good reason, in either case within 12 months following a change in control, then any outstanding time-based equity awards shall immediately accelerate and become fully vested and exercisable or nonforfeitable on the date of termination.

 

The foregoing descriptions of the Original Enright Employment Agreement and the Enright Employment Agreement Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the Original Enright Employment Agreement and the Enright Employment Agreement Amendment, copies of which are filed as Exhibits 10.1 and 10.2, respectively, hereto and are incorporated into this Item 5.02 by reference.

 

Indemnification Agreements

 

Effective as of the Merger Effective Time, the Company entered into indemnification agreements with each of its directors and Executive Officers (the “Indemnification Agreements”). The Indemnification Agreements require the Company, among other things, to indemnify, hold harmless and exonerate each such director and Executive Officer to the fullest extent permitted by applicable law, including the Delaware General Corporation Law, against expenses, judgments, fines, penalties and amounts paid in settlement actually and reasonably incurred in connection with proceedings arising out of such person’s service to the Company, and to advance expenses incurred in connection with such proceedings, subject to certain exceptions and an undertaking to repay advanced amounts if it is ultimately determined that such person is not entitled to indemnification. The Indemnification Agreements also provide procedures for determining entitlement to indemnification and require the Company to use commercially reasonable efforts to maintain directors’ and officers’ liability insurance.

 

The foregoing description of the Indemnification Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Indemnification Agreement, a copy of which is filed as Exhibit 10.3 hereto and is incorporated into this Item 5.02 by reference.

 

 

 

2026 Omnibus Equity Incentive Plan and 2026 Employee Stock Purchase Plan

 

In connection with the Combinations, the Company adopted the Clywedog Therapeutics Holdings, Inc. 2026 Omnibus Equity Incentive Plan (the “Omnibus Plan”) and the Clywedog Therapeutics Holdings, Inc. 2026 Employee Stock Purchase Plan (the “ESPP”). The Company’s directors and executive officers are eligible to participate in the Omnibus Plan, and the Company’s executive officers are eligible to participate in the ESPP, in each case subject to the terms of the applicable plan.

 

The Omnibus Plan is administered by the Compensation Committee (or, with respect to non-employee directors, the board of directors) and provides for the grant of stock options (including incentive stock options and nonqualified stock options), stock appreciation rights, restricted stock, restricted stock units, stock grants, stock units and performance units to members of the board of directors and employees and officers of the Company and its affiliates and subsidiaries, and, on a case-by-case basis, to consultants. The exercise price of options and the base value of stock appreciation rights may not be less than the fair market value of the Common Stock on the date of grant, the term of options and stock appreciation rights may not exceed 10 years, and options and stock appreciation rights may not be repriced without shareholder approval. The aggregate grant date fair value of awards granted to any non-employee director during any fiscal year, together with cash compensation paid for service as a director for that year, may not exceed $750,000.

 

The ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code of 1986, as amended, and is administered by the Compensation Committee. Employees of the Company and its designated subsidiaries who are customarily employed for more than 20 hours per week are generally eligible to participate and may elect to contribute between 2% and 15% of their base wages through payroll deductions during quarterly offering periods. Unless otherwise specified by the Compensation Committee, shares are purchased on the last trading day of each offering period at 85% of the fair market value of the Common Stock on that date, subject to a limit of 15,000 shares per participant per offering period and the $25,000 annual limit under Section 423 of the Code. Employees who would own 5% or more of the Company’s voting power or value are not eligible to participate.

 

The foregoing descriptions of the Omnibus Plan and the ESPP do not purport to be complete and are qualified in their entirety by reference to the full text of the Omnibus Plan and the ESPP, copies of which are filed as Exhibits 10.4 and 10.5 hereto, respectively, and are incorporated into this Item 5.02 by reference.

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Certificate of Amendment – Name Change

 

On November 20, 2026, in connection with the consummation of the Merger, the Company filed a Certificate of Amendment to the A&R Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to change the Company’s corporate name from “Beacon Topco, Inc.” to “Clywedog Therapeutics Holdings, Inc.” The Certificate of Amendment became effective upon filing.

 

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.2 hereto and is incorporated into this Item 5.03 by reference.

 

 

 

Item 9.01Financial Statements and Exhibits.

 

(a) Financial Statements of Businesses Acquired.

 

The unaudited condensed consolidated financial statements of Clywedog Therapeutics, Inc. as of June 30, 2026 and December 31, 2025 and for the three and six months ended June 30, 2026 and 2025 are filed as Exhibit 99.1 hereto and are incorporated herein by reference.

 

The unaudited condensed consolidated financial statements of Clywedog Therapeutics, Inc. as of September 30, 2026 and December 31, 2025 and for the three and nine months ended September 30, 2026 and 2025 will be filed by amendment not later than 71 calendar days after the date this Form 8-K is required to be filed.

 

(b) Pro Forma Financial Information.

 

The unaudited pro forma condensed combined financial statements of Clywedog Therapeutics Holdings, Inc. as of and for the six months ended June 30, 2026 and for the year ended December 31, 2025 are filed as Exhibit 99.2 hereto and are incorporated herein by reference.

 

The unaudited pro forma condensed combined financial statements of Clywedog Therapeutics Holdings, Inc. as of and for the nine months ended September 30, 2026 and for the year ended December 31, 2025 will be filed by amendment not later than 71 calendar days after the date this Form 8-K is required to be filed.

 

(d) Exhibits.

 

Exhibit
Number
  Description of Exhibit
2.1*   Agreement and Plan of Merger, dated as of September 29, 2025, by and among Barinthus Biotherapeutics plc, Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc.), Cdog Merger Sub, Inc. and Clywedog Therapeutics, Inc. (incorporated by reference to Annex A-1 to the proxy statement/prospectus forming part of the Registration Statement on Form S-4 (File No. 333-291359)).
2.2   Amendment to the Agreement and Plan of Merger, dated as of February 22, 2026 (incorporated by reference to Annex A-2 to the proxy statement/prospectus forming part of the Registration Statement on Form S-4 (File No. 333-291359)).
2.3   Amendment No. 2 to the Agreement and Plan of Merger, dated September 22, 2026 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on September 24, 2026).
2.4   Amendment No. 3 to the Agreement and Plan of Merger, dated October 31, 2026 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on November 5, 2026).
3.1   Amended and Restated Certificate of Incorporation of Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc.) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Company on September 17, 2026).
3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc.).
10.1#*   Form of Employment Agreement between Barinthus Bio and William Enright (incorporated by reference to Exhibit 10.10 to Barinthus Bio’s Registration Statement on Form S-1/A (File No. 333-255158)).
10.2#   Amendment to Employment Agreement, dated as of November 20, 2026, by and among Barinthus Bio, Barinthus Bio North America, the Company and William Enright.
10.3#   Form of Indemnification Agreement between Clywedog Therapeutics Holdings, Inc. and each of its directors and executive officers.
10.4#   Clywedog Therapeutics Holdings, Inc. 2026 Omnibus Equity Incentive Plan.
10.5#   Clywedog Therapeutics Holdings, Inc. 2026 Employee Stock Purchase Plan.
99.1   Unaudited condensed consolidated financial statements of Clywedog Therapeutics, Inc. as of June 30, 2026 and December 31, 2025 and for the three and six months ended June 30, 2026 and 2025.
99.2   Unaudited pro forma condensed combined financial statements of Clywedog Therapeutics Holdings, Inc. as of and for the six months ended June 30, 2026 and for the year ended December 31, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

 

# Indicates a management contract or compensatory plan or arrangement.

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 20, 2026 CLYWEDOG THERAPEUTICS HOLDINGS, INC.
     
  By: /s/ William Enright  
  Name: William Enright
  Title: Chief Executive Officer

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 3.2

EXHIBIT 10.2

EXHIBIT 10.3

EXHIBIT 10.4

EXHIBIT 10.5

EXHIBIT 99.1

EXHIBIT 99.2

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: tm2628797d1_8k12b_htm.xml